Researchers at UC San Francisco and UCLA continue to study prostate-specific membrane antigen PET imaging, or PSMA PET, to provide a more effective imaging test for men who have prostate cancer. Last year, this collaboration on a clinical trial led to U.S. Food and Drug Administration (FDA) approval for the technique at both universities, a great first step in leading to more widespread availability of this imaging test to men with prostate cancer. (Read more from UCSF News.)
Recently, the team led by Thomas Hope, MD, associate professor in the UCSF Department of Radiology and Biomedical Imaging, and Jeremie Calais, MD, associate professor in the UCLA Department of Molecular and Medical Pharmacology, published a paper in JAMA Oncology detailing the method that led to FDA approval of PSMA PET and received more good news:
- Inclusion of PSMA PET (both 68Ga-PSMA-11 and 18F-DCFPyL)…
